Topics
Not listed
Modality
Not listed
Study type
Not listed
Abstract
Abstract not available.
Authors
David Killock
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify with the primary paper.
Primary source: PubMed.
Evidence Atlas, updating nightly
Latest literature
Nightly index of recent papers from PubMed, bioRxiv, and medRxiv. Filters are designed for both researcher precision and patient-friendly navigation.
Learn how we rate papers in our methodology.
Starting focus
Cholangiocarcinoma
We’re indexing all cancers but highlighting cholangiocarcinoma while the evidence atlas expands.
Topics
Not listed
Modality
Not listed
Study type
Not listed
Abstract
Abstract not available.
Authors
David Killock
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify with the primary paper.
Primary source: PubMed.
Topics
Treatment
Modality
Targeted therapy
Study type
Review / Meta-analysis
Abstract
Abstract not available.
Authors
Yanmin Deng, Wenrui Huang, Tao Zeng, Yuan Gao
AI-generated summary
Summary not available yet.
This summary may be inaccurate. Verify with the primary paper.
Primary source: PubMed.
Topics
Treatment, Biology / Mechanism, Outcomes / Survival, Epidemiology
Modality
Immunotherapy, Cell therapy, Imaging
Study type
Observational
Abstract
Brain metastases in esophageal adenocarcinoma (EAC) patients are associated with poor prognosis and remain understudied. We performed multi-omics analysis with whole-genome sequencing and single-cell spatial transcriptomics on the brain metastases and matched primary tumors. Our analysis identified ERBB2 as a recurrent oncogene in EAC…
Authors
Lawson, N. M., Ye, L., Cho, C. Y., Zhao, B. +18
AI-generated summary
Recurrent ERBB2 alterations are associated with esophageal adenocarcinoma brain metastases reports: Brain metastases in esophageal adenocarcinoma (EAC) patients are associated with poor prognosis and remain understudied. We performed multi-omics analysis with whole-genome sequencing and single-cell spatial transcriptomics on the brain metastases and matched primary tumors. Our analysis identified ERBB2 as a recurrent oncogene in EAC brain metastases, with 9 out of 10 cases harboring amplifications. This is a preprint and not peer reviewed.
This summary may be inaccurate. Verify with the primary paper.
Primary source: medRxiv (not peer reviewed).